Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A open label, randomized, controled trial to assess the utility of Pitavastatin for patients with type2 diabetes and obesity in Matsuyama Shimin Hospital.

Next Previous
Trial Profile

A open label, randomized, controled trial to assess the utility of Pitavastatin for patients with type2 diabetes and obesity in Matsuyama Shimin Hospital.

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 May 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pitavastatin (Primary) ; Atorvastatin
  • Indications Hyperlipidaemia; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms POM

Most Recent Events

  • 14 Jan 2014 Planned End Date changed from 30 Jun 2014 to 31 Dec 2014, according to University Hospital Medical Information Network - Japan record.
  • 31 May 2013 Planned end date changed from 1 Jun 2013 to 30 Jun 2014 as reported by University Hospital Medical Information Network - Japan.
  • 30 Jun 2012 Planned end date (Jun 2013) added as reported by University Hospital Medical Information Network - Japan.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top